Conference Coverage

Long-acting basal insulin controls HbA1c as well as glargine


 

AT EASD 2015

References

Eli Lilly & Co. funded the study. Dr. Garg has received research funding from the company.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

Weighted CMDS score predicts 15-year diabetes risk
MDedge Cardiology
High troponin T level doubles CVD risk
MDedge Cardiology
Add-on liraglutide effective in obese diabetes patients
MDedge Cardiology
FDA warns of disabling joint pain from DPP-4 inhibitors
MDedge Cardiology
VIDEO: Young hypertensives: Cut back on the caffeine
MDedge Cardiology
VIDEO: Newer type 2 diabetes drugs pose no significant heart failure risk
MDedge Cardiology
Diabetes prevalence rising, especially in black, Asian, and Hispanic populations
MDedge Cardiology
HbA1c aids prediction of atherosclerotic CVD
MDedge Cardiology
High-calorie American diet causes insulin resistance within days
MDedge Cardiology
ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptin
MDedge Cardiology